Nautilus Biotechnology Inc Cash Flow Conversion Efficiency
Nautilus Biotechnology Inc cash flow conversion efficiency. Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) has a cash flow conversion efficiency ratio of -0.105x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.73 Million) by net assets ($131.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nautilus Biotechnology Inc (2018–2025)
Cash flow conversion efficiency of Nautilus Biotechnology Inc from 2018 to 2025. This chart illustrates how Nautilus Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NAUT stock price for real-time trading data and today's change.
Nautilus Biotechnology Inc Cash Flow Conversion Ratio Explained
Nautilus Biotechnology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nautilus Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nautilus Biotechnology Inc ranked by their cash flow conversion efficiency. Also see NAUT market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compucase Enterprise Co Ltd
TW:3032
|
0.180x |
|
BTB Real Estate Investment Trust
TO:BTB-UN
|
0.024x |
|
Launchpad Cadenza Acquisition Corp I Class A Ordinary Share
NASDAQ:LPCV
|
-0.001x |
|
Ammo Inc
NASDAQ:POWW
|
0.014x |
|
Zhejiang Prulde Electric Appliance Co. Ltd. A
SHE:301353
|
N/A |
|
Australian Strategic Materials Ltd
AU:ASM
|
-0.036x |
|
Doubleview Gold Corp
V:DBG
|
0.003x |
|
Huasi Agricultural Development Co Ltd
SHE:002494
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Nautilus Biotechnology Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nautilus Biotechnology Inc from 2018 to 2025. Review financial flexibility index of Nautilus Biotechnology Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $156.97 Million | $-50.70 Million | -0.323x | -13.98% |
| 2024-12-31 | $208.73 Million | $-59.15 Million | -0.283x | -45.40% |
| 2023-12-31 | $265.35 Million | $-51.71 Million | -0.195x | -33.98% |
| 2022-12-31 | $314.92 Million | $-45.81 Million | -0.145x | -34.76% |
| 2021-12-31 | $363.58 Million | $-39.24 Million | -0.108x | -122.92% |
| 2020-12-31 | $-29.72 Million | $-14.00 Million | 0.471x | +187.98% |
| 2019-12-31 | $18.05 Million | $-9.66 Million | -0.535x | +98.88% |
| 2018-12-31 | $5.00 Million | $-238.30 Million | -47.660x | -- |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument,… Read more